Literature DB >> 31200957

CircSAMD4A accelerates cell proliferation of osteosarcoma by sponging miR-1244 and regulating MDM2 mRNA expression.

Zhao Yanbin1, Zhang Jing2.   

Abstract

Here, we firstly examined the proliferation and invasion capacities of different osteosarcoma (OS) cell lines, and analyzed the profiling of the differentially expressed circular RNAs(circRNAs). Then, we identified a novel circRNA(circ_101356/circ_0004846, we named circSAMD4 in the present study) and found it was highly expressed in the OS tissues compared to adjacent non-cancerous tissues. Furthermore, we indicated that circSAMD4A promoted OS proliferation in vivo and in vitro. In addition, we proved that circSAMD4A enhances osteosarcoma cells stemness features. In mechanism, circSAMD4A could sponge miR-1244 in OS cells. Moreover, we verified that MDM2 was a target of miR-1244. In conclusion, circSAMD4A/miR-1244/MDM2 regulatory loop might be a promising therapeutic target for OS treatment.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  MDM2; Osteosarcoma; Proliferation; circSAMD4A; miR-1244

Mesh:

Substances:

Year:  2019        PMID: 31200957     DOI: 10.1016/j.bbrc.2019.05.182

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

1.  circSamd4 represses myogenic transcriptional activity of PUR proteins.

Authors:  Poonam R Pandey; Jen-Hao Yang; Dimitrios Tsitsipatis; Amaresh C Panda; Ji Heon Noh; Kyoung Mi Kim; Rachel Munk; Thomas Nicholson; Douglas Hanniford; Diana Argibay; Xiaoling Yang; Jennifer L Martindale; Ming-Wen Chang; Simon W Jones; Eva Hernando; Payel Sen; Supriyo De; Kotb Abdelmohsen; Myriam Gorospe
Journal:  Nucleic Acids Res       Date:  2020-04-17       Impact factor: 16.971

Review 2.  The emerging roles of circular RNAs in vessel co-option and vasculogenic mimicry: clinical insights for anti-angiogenic therapy in cancers.

Authors:  Ying Shao; Bingjian Lu
Journal:  Cancer Metastasis Rev       Date:  2021-10-18       Impact factor: 9.264

3.  CircSAMD4A contributes to cell doxorubicin resistance in osteosarcoma by regulating the miR-218-5p/KLF8 axis.

Authors:  Wei Wei; Liefeng Ji; Wanli Duan; Jiang Zhu
Journal:  Open Life Sci       Date:  2020-11-24       Impact factor: 0.938

4.  Down-regulation of circular RNA hsa_circ_0007534 suppresses cell growth by regulating miR-219a-5p/SOX5 axis in osteosarcoma.

Authors:  Peng Zhang; Jun Li
Journal:  J Bone Oncol       Date:  2021-01-18       Impact factor: 4.072

5.  Circ_0056285 Regulates Proliferation, Apoptosis and Glycolysis of Osteosarcoma Cells via miR-1244/TRIM44 Axis.

Authors:  Shousong Huo; Dongmei Dou
Journal:  Cancer Manag Res       Date:  2021-02-10       Impact factor: 3.989

6.  Circ_001569 regulates FLOT2 expression to promote the proliferation, migration, invasion and EMT of osteosarcoma cells through sponging miR-185-5p.

Authors:  Bin Xiao; Xusheng Zhang; Xiaojuan Li; Zhipeng Zhao
Journal:  Open Life Sci       Date:  2020-07-10       Impact factor: 0.938

7.  Decreased circUBAP2 Expression Is Associated with Preeclampsia by Limiting Trophoblast Cell Proliferation and Migration.

Authors:  Tingting Qi; Di Zhang; Xuting Shi; Minhui Li; Hongbin Xu
Journal:  Reprod Sci       Date:  2021-01-27       Impact factor: 3.060

8.  Circ_0001721 enhances doxorubicin resistance and promotes tumorigenesis in osteosarcoma through miR-758/TCF4 axis.

Authors:  Huapeng Guan; Hao Xu; Jinshui Chen; Weishan Wu; Dongfeng Chen; Yungang Chen; Jianzhong Sun
Journal:  Cancer Cell Int       Date:  2021-07-02       Impact factor: 5.722

9.  Global transcriptomic study of circRNAs expression profile in sorafenib resistant hepatocellular carcinoma cells.

Authors:  Man-Ya Wu; Yan-Ping Tang; Jun-Jie Liu; Rong Liang; Xiao-Ling Luo
Journal:  J Cancer       Date:  2020-03-04       Impact factor: 4.207

10.  Upregulation Of circMMP9 Promotes Osteosarcoma Progression Via Targeting miR-1265/CHI3L1 Axis.

Authors:  Guangjie Pan; Ting Hu; Xuewu Chen; Chao Zhang
Journal:  Cancer Manag Res       Date:  2019-10-29       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.